CN112972524A - Application of schisandra chinensis oil in inhibition of sebaceous gland activity - Google Patents
Application of schisandra chinensis oil in inhibition of sebaceous gland activity Download PDFInfo
- Publication number
- CN112972524A CN112972524A CN202110368972.6A CN202110368972A CN112972524A CN 112972524 A CN112972524 A CN 112972524A CN 202110368972 A CN202110368972 A CN 202110368972A CN 112972524 A CN112972524 A CN 112972524A
- Authority
- CN
- China
- Prior art keywords
- sebaceous gland
- oil
- schisandra chinensis
- inhibition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001732 sebaceous gland Anatomy 0.000 title claims abstract description 74
- 235000008422 Schisandra chinensis Nutrition 0.000 title claims abstract description 49
- 230000000694 effects Effects 0.000 title claims abstract description 45
- 240000006079 Schisandra chinensis Species 0.000 title claims abstract description 44
- 230000005764 inhibitory process Effects 0.000 title claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 20
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 11
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 6
- 206010000496 acne Diseases 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 61
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 20
- 102000001307 androgen receptors Human genes 0.000 claims description 13
- 108010080146 androgen receptors Proteins 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000011344 liquid material Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 abstract description 18
- 230000028327 secretion Effects 0.000 abstract description 17
- 230000035755 proliferation Effects 0.000 abstract description 14
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000001276 controlling effect Effects 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 49
- 239000000243 solution Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 241000699673 Mesocricetus auratus Species 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 9
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 241000736075 Schisandra Species 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000010674 schisandra oil Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- RWZVFCIPMBYBCY-UHFFFAOYSA-N methyl 2,2-dihydroxyoctadecanoate Chemical compound CCCCCCCCCCCCCCCCC(O)(O)C(=O)OC RWZVFCIPMBYBCY-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application belongs to the technical field of biological medicines. The application provides application of schisandra chinensis oil in inhibiting sebaceous gland activity. Experimental results show that the schisandra chinensis oil can obviously inhibit the proliferation of sebaceous gland cells, inhibit the lipid synthesis of the sebaceous gland cells and reduce the expression of sebaceous gland cell receptors at the cellular level, and realizes the effects of inhibiting the growth of sebaceous gland plaques and inhibiting the sebum secretion, so that the schisandra chinensis oil has the effects of inhibiting the sebaceous gland activity, controlling oil, regulating the water-oil balance of the face and the like, can be applied to medicaments for treating acne or oil-controlling cosmetics, and has the advantages of safety, high efficiency and low cost.
Description
Technical Field
The application belongs to the technical field of biomedicine, and particularly relates to application of schisandra chinensis oil in inhibition of sebaceous gland activity.
Background
Schisandra chinensis (Schisandra chinensis) is a dry mature fruit of Schisandra chinensis (Schisandra chinensis) belonging to Magnoliaceae, and is listed as the top grade in Shen nong Ben Cao Jing. The book of Xin Xiu Ben Cao records that the five flavors of skin and meat are sweet and sour, and bitter in the kernel, all have salty taste, so it is named as Wu Wei Zi. The schisandra fruit has the functions of nourishing and strengthening and has high medicinal and edible values. Chemical research shows that the schisandra chinensis mainly contains lignans, volatile oils, flavonoids, terpenes, organic acids and other active ingredients, and pharmacological research shows that the schisandra chinensis has the effects of protecting liver, tranquilizing and hypnotizing, reducing blood sugar, resisting oxidation, enhancing immunity, resisting cancer, resisting AIDS virus and the like. However, the schisandra chinensis has not been reported to inhibit the sebaceous gland activity.
The main components of sebum include triglyceride, wax ester, squalene, cholesterol ester and cholesterol. Sebaceous glands are a kind of glandular full-plasma secretory tissue distributed in the skin of the whole body except palms and soles, and have the highest density on the scalp and face. The normal lipid on the skin surface can play a barrier role, can moisten the skin, resist infection and maintain the bacteria state balance on the skin surface of a human body. Excessive sebum secretion from sebaceous glands leads to excessive skin oil production and aesthetic problems, and may also promote the development of acne or other diseases, which seriously affect the mental health and quality of life of patients.
The breakdown of keratinocytes and the sebum secreted by the sebaceous glands constitute the major source of lipids on the skin surface. Among them, the breakdown of keratinocytes produces only a small fraction of the lipids, and the excessive sebum secretion from the sebaceous glands is the main cause of the greasiness of the skin. The sebaceous gland function is regulated by a plurality of factors, and androgen is taken as a primary factor influencing sebum secretion and mainly regulates the differentiation and proliferation of the sebaceous gland and the synthesis and secretion of sebum. In addition, sebaceous gland function is also regulated by enzyme systems such as Peroxisome Proliferator Activated Receptors (PPARs), neuropeptides, antimicrobial peptides, inflammatory cytokines, and the like.
At present, western medicines are mainly used for effectively inhibiting sebaceous gland secretion, and have the defects of multiple side effects and strong dependence, so that a safe and effective substitute component is urgently needed.
Disclosure of Invention
In view of the above, the present application provides an application of schizandra chinensis oil in inhibiting sebaceous gland activity, wherein the schizandra chinensis oil can significantly inhibit growth of sebaceous gland plaques and sebum secretion at an animal level.
The specific technical scheme of the application is as follows:
in a first aspect, the application provides the use of schizandra chinensis oil for inhibiting sebaceous gland activity.
Preferably, the inhibition of sebaceous gland activity is specifically inhibition of sebaceous gland cell proliferation.
Preferably, the inhibition of the sebaceous gland activity is specifically inhibition of lipid synthesis by sebaceous gland cells.
Preferably, the inhibition of sebaceous gland activity is specifically the down-regulation of the expression of androgen receptor mRNA of sebaceous gland cells.
Preferably, the schisandra chinensis oil is volatile oil obtained by extracting schisandra chinensis fruits.
Preferably, the step of extracting comprises: crushing fructus schizandrae, sieving with a 14-60-mesh sieve, adding the crushed powder into an aqueous solution of NaCl according to the liquid-material mass ratio of 4-8 times, soaking for 2-4 hours, then carrying out water distillation for 2-5 hours, and collecting the upper essential oil.
More preferably, the step of extracting comprises: pulverizing fructus Schisandrae, sieving with 40 mesh sieve, soaking the pulverized powder in 6 times of distilled water containing 6% NaCl for 3 hr, distilling with water for 3 hr, collecting upper layer essential oil, and adding anhydrous NaSO4Drying and filtering to obtain the product.
In the application, animal level experiments show that the schisandra chinensis oil can obviously inhibit the proliferation of sebaceous gland cells, inhibit the synthesis of lipid by the sebaceous gland cells and reduce the expression of a sebaceous gland cell receptor at a cell level, so that the effects of inhibiting the growth of sebaceous gland plaques and inhibiting the secretion of sebum are realized, and the schisandra chinensis oil has good development potential.
In a second aspect, the application provides the use of schizandra chinensis oil in the preparation of a medicament for treating acne.
Preferably, the medicament is in the form of emulsion or paste.
In a third aspect, the application provides application of schisandra chinensis oil in preparing oil-control cosmetics.
Preferably, the cosmetic is in the form of water, lotion, essence or facial mask.
In the application, the schisandra chinensis oil can obviously inhibit the growth of sebaceous gland plaques and sebum secretion at the animal level, so that the schisandra chinensis oil has the effects of inhibiting the activity of sebaceous glands, controlling oil, regulating the water-oil balance of the face and the like, can be applied to medicaments for treating acne or oil-control cosmetics, and has the advantages of safety, high efficiency and low cost.
In summary, the application provides an application of schisandra chinensis oil in inhibition of sebaceous gland activity. Experimental results show that the schisandra chinensis oil can obviously inhibit the proliferation of sebaceous gland cells, inhibit the lipid synthesis of the sebaceous gland cells and reduce the expression of sebaceous gland cell receptors at the cellular level, and realizes the effects of inhibiting the growth of sebaceous gland plaques and inhibiting the sebum secretion, so that the schisandra chinensis oil has the effects of inhibiting the sebaceous gland activity, controlling oil, regulating the water-oil balance of the face and the like, can be applied to medicaments for treating acne or oil-controlling cosmetics, and has the advantages of safety, high efficiency and low cost.
Drawings
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings needed to be used in the description of the embodiments or the prior art will be briefly introduced below, and it is obvious that the drawings in the following description are only some embodiments of the present application, and it is obvious for those skilled in the art that other drawings can be obtained according to the drawings without inventive exercise.
FIG. 1 is the sebum secretion amount of sebaceous gland plaques of mice with golden yellow color at 0, 10, 20, 30d before and after administration of schizandra chinensis oil (left side) in example 5;
FIG. 2 is the sebum secretion amount of sebaceous gland plaques of mice with golden yellow color at 0, 10, 20, 30d before and after administration of the schisandra fruit oil in example 5 (right side).
Detailed Description
In order to make the objects, features and advantages of the present application more obvious and understandable, the technical solutions in the embodiments of the present application are clearly and completely described, and it is obvious that the embodiments described below are only a part of the embodiments of the present application, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present application.
The starting materials and reagents used in the examples of the present application are commercially available, and the experimental procedures used are routine in the art unless otherwise specified.
The golden hamster of the embodiment of the application is purchased from Guangdong province medical animal experiment center, SZ95 cells are purchased from Hongbao Biotechnology Limited, Shenzhen, propylene glycol is purchased from Tianjin Mao chemical reagent factory, chloral hydrate is purchased from Sigma-Aldrich, DMSO is purchased from Tianjin Mao chemical reagent factory, Nile Red fluorescent dye solution is purchased from Shanghai Huling Biotech Limited, reverse transcription kit is purchased from Promega, Trizol is purchased from Gibco, dNTP is purchased from Guangzhou Dongshan Biotech Limited, MgCl2Purchased from Shanghai Aladdin Biotechnology Ltd.
Example 1 extraction of Schisandra chinensis oil
Pulverizing fructus Schisandrae, sieving with 40 mesh sieve, soaking the pulverized powder in 6 times of distilled water containing 6% NaCl for 3 hr, distilling with water for 3 hr, collecting upper layer essential oil, and adding anhydrous NaSO4Drying and filtering to obtain the product.
Example 2 Effect of Schisandra chinensis oil on the proliferation of sebaceous gland cells
(1) Culturing human sebaceous gland cells (SZ95 cells), and digesting SZ95 cells by trypsin to prepare SZ95 cell suspension when the cells grow and fuse to reach 80%;
(2) inoculating the SZ95 cell suspension to a 96-well culture plate, wherein each well comprises 4000 cells, culturing for 48h, removing the supernatant, washing for 2 times by using PBS solution, respectively adding the culture medium containing 0.5, 5, 50 and 500 mug/mL of the schisandra chinensis oil prepared in the example 1, continuously culturing for 48h, removing the supernatant, and washing for 2 times by using the PBS solution;
(3) 0.5mg/mL MTT 100u1 was added, after 4h incubation, MTT was discarded, 150. mu.L DMMS 0 was added to each well and incubated for 10 min. The absorbance was measured using a microplate reader at a wavelength of 490 nm.
3 parallel wells were set for each effect concentration, and medium without schizandra oil was added as a blank group, medium without addition of SZ95 cells and without schizandra oil was added as a blank control group, and medium at each effect concentration was added without addition of SZ95 cells as a zero-adjustment group. The results of the effect of schizandra chinensis oil on the proliferation rate of SZ95 cells in example 2 of the present application are shown in table 1, wherein the proliferation rate of SZ95 cells in the blank group is blank OD-blank OD, and the proliferation rate of SZ95 cells in the experimental group is (experimental OD-zero-adjustment OD)/(blank OD-blank OD).
TABLE 1 Effect of Schisandra chinensis oil on the proliferation Rate of SZ95 cells
Group of | Cell proliferation Rate (%) of SZ95 |
Blank group | 100±4.8860 |
0.5. mu.g/ml test group | 96.67±4.0787 |
5 μ g/ml test group | 86.10±4.0398* |
50 μ g/ml experimental group | 71.09±7.6650*** |
500 μ g/ml experimental group | 46.71±8.3923*** |
Note: p < 0.05, P < 0.001, compared to blank
As can be seen from Table 1, 0.5. mu.g/ml schizandra chinensis oil has no significant inhibition effect on the proliferation of sebaceous gland cells (P is more than 0.05); the schisandra chinensis oil with the concentration of 5 mu g/ml has obvious inhibition effect on the proliferation of sebaceous gland cells (P is less than 0.01); 50. the Schisandra chinensis oil with the concentration of 500 mu g/ml has stronger inhibition effect on the proliferation of sebaceous gland cells (P is less than 0.001).
Example 3 Effect of Schisandra chinensis oil on sebaceous gland cell lipid Synthesis
(1) Culturing SZ95 cells, and digesting the SZ95 cells by trypsin to prepare SZ95 cell suspension when the cells grow and fuse to reach 80%;
(2) SZ95 cells were seeded in 6-well plates at 2X 10 per well5After further culturing for 48 hours, medium containing 0.5, 5, 50 and 500. mu.g/mL of the schisandra oil prepared in example 1 was added. Continuing culturing for 48h, adding trypsin for digestion, stopping digestion with a culture medium containing 10% fetal calf serum, and washing with PBS solution for 2 times to prepare single cell suspension;
(3) nile red fluorescent dye solution was added to a final concentration of 100 ng/mL. Incubate at room temperature for 15min, and filter with 300 mesh nylon filter. The fluorescence intensity of 10000 cells per group was measured by flow cytometry. Finally, the mean fluorescence intensity (excitation wavelength 485nm, emission wavelength 565nm) of each cell was calculated.
3 parallel wells were set for each effect concentration, and medium without schizandra oil was added as a blank. The results of the effect of schizandra chinensis oil on the synthesis of SZ95 cell lipids in example 3 of the present application are shown in table 2, wherein the inhibition ratio of the experimental group is (1-experimental group fluorescence unit/blank group fluorescence unit) × 100%.
TABLE 2 Effect of Schisandra chinensis oil on SZ95 cell lipid synthesis
Group of | Mean fluorescence unit | Inhibition ratio (%) |
Blank group | 649.33±46.0145 | - |
0.5. mu.g/ml test group | 629.67±28.1484 | 3.03 |
5 μ g/ml test group | 574.90±32.4553 | 11.46 |
50 μ g/ml experimental group | 458.21±52.0152*** | 29.43 |
500 μ g/ml experimental group | 497.50±44.9246** | 23.38 |
Note: p < 0.01, P < 0.001, compared to blank
As can be seen from Table 2, 0.5 and 5. mu.g/ml schizandra chinensis oil had insignificant inhibitory effects on sebaceous gland cell lipid synthesis (P > 0.05); the inhibitory effect of 50 and 500 mu g/ml schisandra fruit oil on the proliferation of sebaceous gland cells is obvious (P is less than 0.01 and P is less than 0.001 respectively).
Example 4 Effect of Schisandra chinensis oil on the expression of Androgen Receptor (AR) mRNA of sebaceous gland cells
(1) Culturing SZ95 cells, and digesting SZ95 cells by trypsin to prepare SZ95 cell suspension when the cells grow and fuse to 80%;
(2) SZ95 cells were seeded in 6-well plates at 2X 10 per well5Respectively adding into culture medium after culturing for 96h0.5, 5, 50 and 500. mu.g/mL of the medium of Schisandra chinensis oil prepared in example 1. After further incubation for 24h, Trizol was added and total RNA was extracted from SZ95 cells according to the instructions. The cDNA was synthesized by reverse transcription following the reverse transcription kit instructions, followed by in-line amplification of AR and β -actin (β -actin). The primer sequence is as follows: the AR sense strand: 5'-GAAGACCTGCCTGATCTGTG-3', antisense strand: 5 '-AAGCCTCTCCITCCTCCTGT-3' (product length 269 bp); internal reference beta-actin sense strand: 5'-AGAGATGGCCACGGCTGCTT-3', antisense strand: 5'-ATTTGCGGTGGACGATGGAG-3' (product length 445 bp). The reaction system is 25 μ L: wherein PCR 10 Xbuffer 2.5. mu.L, 10mmol/L dNTP mixture 0.5. mu.L, 25mol/L MgCl2mu.L of 2. mu.L of each of the sense and antisense strands of AR (20pmoL/L), 0.2. mu.L of each of the sense and antisense strands of beta-actin (20pmoL/L), 1.25U of Taq DNA polymerase, 10. mu.L of cDNA, and finally deionized water to a total volume of 25. mu.L. The reaction conditions are as follows: 30s at 94 ℃, 45s at 60 ℃ and 30s at 72 ℃ for 40 cycles. The RT-PCR products were electrophoresed on a 20% agarose gel and stained with 0.5% ethidium bromide. And analyzing the scanning result by adopting a Shanghai energy gel imaging analysis system.
3 parallel wells were set for each effect concentration, and medium without schizandra oil was added as a blank. The absorbance value takes the product of the intensity and the net area as a quantitative standard, and the ratio of the absorbance value of the specific product and the absorbance value of the beta-actin as a semi-quantitative value. The results of the effect of schizandra chinensis oil on the expression of the androgen receptor mRNA of SZ95 cells in example 4 of the present application are shown in table 3, wherein the expression level is experimental group (blank group) absorbance/β -actin absorbance.
TABLE 3 Effect of Schisandra chinensis oil on the expression of Androgen Receptor (AR) mRNA of SZ95 cells
Group of | Amount of expression |
Blank group | 0.632±0.0215 |
0.5. mu.g/ml test group | 0.642±0.0210 |
5 μ g/ml test group | 0.561±0.0331* |
50 μ g/ml experimental group | 0.464±0.0319**** |
500 μ g/ml experimental group | 0.532±0.0251** |
Note: p < 0.05, P < 0.01, P < 0.0001 compared to blank
As can be seen from Table 3, 0.5. mu.g/ml schizandra oil failed to inhibit the expression of the mRNA of androgen receptor of sebaceous gland cells (P > 0.05); 5. the inhibitory effect of 50 and 500 mu g/ml schisandra fruit oil on the mRNA expression of androgen receptor of sebaceous gland cells is obvious (P is less than 0.05, P is less than 0.0001 and P is less than 0.01 respectively).
Example 5 inhibitory Effect of Schisandra chinensis oil on sebum secretion
(1) Respectively dissolving 25mg and 100mg of the schisandra chinensis oil prepared in the example 1 in propylene glycol, wherein the total volume of the solution is 10mL, and preparing 2.5mg/mL and 10mg/mL schisandra chinensis oil solutions;
(2) 18 male golden yellow hamster are selected, aged for 6 weeks, and the weight of the male golden yellow hamster is 100g +/-20 g, and the male golden yellow hamster is adaptively raised for 3 days before the experiment. The golden hamster was divided into three groups, a blank group (control) was not administered, a low concentration test group (L-SC) was coated with 2.5mg/mL of a schisandra oil solution, and a high concentration test group (H-SC) was coated with 10mg/mL of a schisandra oil solution. 24 hours before application on the first day, the lateral flank hair of each group of golden hamster was shaved and depilatory cream was used to remove hair again, fully exposing the sebaceous glands. Spreading oleum Schisandrae chinensis solution with different concentrations on sebaceous glands of golden hamster 20 μ L each side once a day for 30 days;
(3) after anesthetizing golden hamster by intraperitoneal injection of chloral hydrate at 0, 10, 20 and 30d, respectively, the maximum transverse Diameter (DT) and the maximum longitudinal Diameter (DL) of sebaceous gland plaques were measured with a vernier caliper, and the change of each group of plaques pi × DT × DL was calculated. After anesthetizing the golden hamster by intraperitoneal injection of chloral hydrate for 0, 10, 20 and 30 days, the skin oil and fat were measured by a CK skin tester.
The data are expressed as X + -S, and the difference between groups is compared by t-test. In example 5 of the present application, the comparison of sizes of sebaceous glands of mice with golden yellow color before and after administration of schizandra chinensis oil is shown in table 4 (left side), and the comparison of sizes of sebaceous glands of mice with golden yellow color before and after administration of schizandra chinensis oil is shown in table 5 (right side).
TABLE 4 comparison of size of sebaceous gland plaques of golden hamster before and after administration of Schisandra chinensis oil (left side) (unit: mm)2)
Group of | Number of examples | Area before | Area | 30 days after application |
Blank group | 6 | 36.82±2.7563 | 56.00±1.8890 | |
Low concentration test group | 6 | 36.25±1.4849 | 48.00±3.2239** | |
High concentration test group | 6 | 35.85±3.7546 | 46.03±4.9922** |
Note: p < 0.05, P < 0.01, compared to blank
TABLE 5 comparison of size of sebaceous gland plaques of golden hamster before and after administration of Schisandra chinensis oil (right side) (unit: mm)2)
Group of | Number of examples | Area before | Area | 30 days after application |
Blank group | 6 | 36.54±1.0738 | 57.22±4.2068 | |
Low concentration test group | 6 | 36.45±3.3789 | 53.87±7.8266 | |
High concentration test group | 6 | 36.50±4.0583 | 48.41±4.9341* |
Note: p < 0.05, P < 0.01, compared to blank
As can be seen from tables 4 and 5, the areas of the groups before administration were comparable without significant difference (P > 0.05). The sebaceous gland plaques of the golden hamster in the blank group, the low-concentration experimental group and the high-concentration experimental group are increased compared with those before treatment, but the sebaceous gland plaques in the low-concentration experimental group and the high-concentration experimental group are reduced compared with those in the blank group, and the inhibition effect of the high-concentration schisandra fruit oil on the sebaceous gland plaque increase is remarkably different (P is less than 0.01).
Sebum secretion amounts of sebaceous gland plaques of golden hamster at 0, 10, 20, 30d before and after administration of schizandra chinensis oil in example 5 of the present application are shown in fig. 1 (left side) and fig. 2 (right side). Fig. 1 and 2 show that sebum secretion from sebaceous plaques on both left and right sides of golden yellow hamster is significantly reduced in the low and high concentration experimental group compared to the blank group after 30 days of administration. Wherein, the high-concentration schisandra chinensis oil has better inhibition effect on sebum secretion of golden hamster.
The experimental results show that the schisandra chinensis oil can inhibit the proliferation of sebaceous gland cells, inhibit the synthesis of lipid by the sebaceous gland cells and reduce the expression of androgen receptor mRNA of the sebaceous gland cells, thereby realizing the effects of inhibiting the growth of sebaceous gland plaques and inhibiting the secretion of sebum and having good development potential.
The above embodiments are only used for illustrating the technical solutions of the present application, and not for limiting the same; although the present application has been described in detail with reference to the foregoing embodiments, it should be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions in the embodiments of the present application.
Claims (10)
1. Use of Schisandra chinensis oil for inhibiting sebaceous gland activity is provided.
2. Use according to claim 1, wherein the inhibition of sebaceous gland activity is in particular inhibition of sebaceous gland cell proliferation.
3. Use according to claim 1, wherein the inhibition of sebaceous gland activity is in particular inhibition of lipid synthesis by sebaceous gland cells.
4. The use according to claim 1, wherein said inhibition of sebaceous gland activity is in particular down-regulation of the expression of the androgen receptor mRNA of sebaceous gland cells.
5. The use of claim 1, wherein the schizandra chinensis oil is an essential oil extracted from the fruit of schizandra chinensis.
6. The use according to claim 5, wherein the step of extracting comprises: crushing fructus schizandrae, sieving with a 14-60-mesh sieve, adding the crushed powder into an aqueous solution of NaCl according to the liquid-material mass ratio of 4-8 times, soaking for 2-4 hours, then carrying out water distillation for 2-5 hours, and collecting the upper essential oil.
7. Application of Schisandra chinensis oil in preparing medicine for treating acne is provided.
8. The use according to claim 7, wherein the medicament is in the form of an emulsion or an ointment.
9. Application of Schisandra chinensis oil in preparing oil-controlling cosmetics is provided.
10. The use according to claim 9, characterized in that the cosmetic is in the form of water, a lotion, a serum or a mask.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110368972.6A CN112972524B (en) | 2021-04-06 | 2021-04-06 | Application of schisandra chinensis oil in inhibition of sebaceous gland activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110368972.6A CN112972524B (en) | 2021-04-06 | 2021-04-06 | Application of schisandra chinensis oil in inhibition of sebaceous gland activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112972524A true CN112972524A (en) | 2021-06-18 |
CN112972524B CN112972524B (en) | 2022-10-04 |
Family
ID=76339096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110368972.6A Active CN112972524B (en) | 2021-04-06 | 2021-04-06 | Application of schisandra chinensis oil in inhibition of sebaceous gland activity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112972524B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116549512A (en) * | 2023-07-12 | 2023-08-08 | 江西瑞秀朗科技有限公司 | Compound essential oil for treating acne and pharmaceutical composition containing compound essential oil |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102481245A (en) * | 2009-07-30 | 2012-05-30 | 法国科延公司 | Cosmetic Composition For The Treatment Of Acne Comprising A Peptide Extract Of Schizandra |
CN104546611A (en) * | 2015-01-14 | 2015-04-29 | 上海相宜本草化妆品股份有限公司 | Application of deoxyschizandrin in preparation of cosmetics or externally-applied medicines with functions of resisting light aging or removing acnes and diminishing inflammation |
KR20150064515A (en) * | 2013-12-03 | 2015-06-11 | 주식회사 바이오에프디엔씨 | Anti-aging Composition for Skin External Application Comprising Magnoliale Placenta Culture Extracts |
CN110037946A (en) * | 2019-06-04 | 2019-07-23 | 河南发发发生物科技有限公司 | A kind of black hair Hair-conditioning essential oil and preparation method thereof |
-
2021
- 2021-04-06 CN CN202110368972.6A patent/CN112972524B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102481245A (en) * | 2009-07-30 | 2012-05-30 | 法国科延公司 | Cosmetic Composition For The Treatment Of Acne Comprising A Peptide Extract Of Schizandra |
KR20150064515A (en) * | 2013-12-03 | 2015-06-11 | 주식회사 바이오에프디엔씨 | Anti-aging Composition for Skin External Application Comprising Magnoliale Placenta Culture Extracts |
CN104546611A (en) * | 2015-01-14 | 2015-04-29 | 上海相宜本草化妆品股份有限公司 | Application of deoxyschizandrin in preparation of cosmetics or externally-applied medicines with functions of resisting light aging or removing acnes and diminishing inflammation |
CN110037946A (en) * | 2019-06-04 | 2019-07-23 | 河南发发发生物科技有限公司 | A kind of black hair Hair-conditioning essential oil and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
GUO M等: "Comparative effects of schisandrin A,B,and C on propionibacterium acnes-induced,NLRP3 inflammasome activation-medicated IL-1β secretion and pyroptosis", 《BIOMED PHARMACOTHER》 * |
李东霖等: "痤疮研究进展", 《昆明医科大学学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116549512A (en) * | 2023-07-12 | 2023-08-08 | 江西瑞秀朗科技有限公司 | Compound essential oil for treating acne and pharmaceutical composition containing compound essential oil |
CN116549512B (en) * | 2023-07-12 | 2023-10-27 | 江西瑞秀朗科技有限公司 | Compound essential oil for treating acne and pharmaceutical composition containing compound essential oil |
Also Published As
Publication number | Publication date |
---|---|
CN112972524B (en) | 2022-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101047644B1 (en) | External skin composition containing pogongyoung, horse riding, powder or extract extract | |
KR101412500B1 (en) | Cosmetic composition for improving atopic skin comprising herb extract fermented in bamboo cylinder and manufacturing method thereof | |
KR102587666B1 (en) | Cosmetic composition comprising stabilized glutathione by lipid nanoparticles and physiologically active materials | |
CN101721507B (en) | Composition for relieving and treating fatty livers and preparation method thereof | |
KR101300701B1 (en) | The cosmetics to have an atopic dermatitis improvement efficacy making method besides | |
KR101098400B1 (en) | A method for mucus of acusta despecta sieboldiana feed red ginseng and cosmetic composition containing thereof | |
CN112972524B (en) | Application of schisandra chinensis oil in inhibition of sebaceous gland activity | |
KR20150010691A (en) | Hair loss preventing, skin and scalp protecting herbal cosmetic composition containing extracts of saxifrage, coptis, houttuynia, ginseng, peony root, paeonia suffruticosa, yeast and pleuropterus multiflorus, and its manufacturing method | |
KR101400264B1 (en) | Compositions for enhancing skin barrier comprising mixture extract of Citrus unshiu Markovich and Achyranthes fauriei | |
KR102598042B1 (en) | Composition having centipeda minima extracts for anti-inflammatory, preventing and curing autoimmune disease and manufacturing method thereof | |
JP6154606B2 (en) | Antioxidant or whitening cosmetic composition containing an extract of Korean medicine | |
KR102510062B1 (en) | Hair care cosmetic composition for preventing hair loss comprising mixed herbal medicine extract and aroma oil | |
CN102326813A (en) | Salvia miltiorrhiza bge.f.alba functional beverage and preparation method thereof | |
JP2005220100A (en) | Anti-ageing agent, platelet aggregation inhibitor, antioxidant, anti-allergic agent, skin cosmetic, and food and drink | |
CN104491499A (en) | Skin-care powder with efficacy of removing scars and acne marks | |
KR20090049390A (en) | The manufacturing method of natural unfalling out of hair | |
CN110840785B (en) | Cosmetic composition for improving skin aging or skin wrinkles | |
KR101188216B1 (en) | Natural complex extract Composition for preventing falling out of the hair and promoting growth of the hair containing black soybean paste's active principle | |
KR102031418B1 (en) | Pharmaceutical Compositions Comprising Zizyphus jujuba var. spinosa Composite oil Having Anti-atopic Dermatitis | |
KR102302734B1 (en) | COMPOSITION COMPRISING EXTRACT OF POLYGONUM CUSPIDATUM SIEB. et ZUCC. AND CINNAMOMUM CASSIA BLUME FOR PREVENTING, IMPROVING OR TREATING OF BONE LOSS RELATED DISEASE | |
KR102513966B1 (en) | Cosmetic composition for anti-inflammatory and skin surpression comprising nanoliposome | |
JP6017259B2 (en) | Endothelin action inhibitor | |
KR102471051B1 (en) | Composition for preventing and alleviating redness and atopy using natural materials, and cosmetics containing the same | |
KR101979658B1 (en) | Manufacturing method of composition for hair-loss prevention and hair growth using shungite | |
KR102411893B1 (en) | Composition for inhibiting sebum secretion comprising Chestnut bur extract as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |